Search
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions
Categories: Compounds used in a research, industrial, or household settingEtorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedA narcotic analgesic morphinan used as a sedative in veterinary practice. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.
Endostatin
go.drugbank.com/drugs/DB06423InvestigationalCategories: Compounds used in a research, industrial, or household settingSodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnIt acts as an emulsifier and pH control agent in food products [L2590]. … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Modakafusp alfa
go.drugbank.com/drugs/DB16399InvestigationalMultiple Myeloma (MM)). … Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Trichophyton rubrum
go.drugbank.com/drugs/DB10915ApprovedTrichophyton rubrum extract is used in allergenic testing.
Mixtures: Trichophyton for Intradermal Skin Testing